Impact of Adjunct Testosterone on Cancer-Related Fatigue: An Ancillary Analysis from a Controlled Randomized Trial

Area of Science:

• Oncology
• Endocrinology
• Clinical Trials

Background:

• Cancer-related fatigue (CRF) is a common and debilitating side effect of cancer treatment.
• Inflammatory markers are linked to CRF, but targeted treatments are not standard.
• Previous research suggested testosterone may preserve lean body mass in cancer patients.

Purpose of the Study:

• To investigate if testosterone therapy reduces inflammatory burden in cancer patients.
• To determine if testosterone therapy improves cancer-related fatigue (CRF) symptoms.
• To assess the impact of testosterone on health-related quality of life and functional measures.

Main Methods:

• An ancillary analysis of a randomized, double-blind, placebo-controlled trial (NCT00878995).
• 24 advanced cancer patients were randomized to receive weekly testosterone injections (100 mg) or placebo.
• Outcomes assessed included CRF symptoms, inflammatory markers, quality of life, and performance measures.

Main Results:

• Testosterone therapy did not significantly ameliorate CRF symptoms compared to placebo.
• No significant improvements were observed in inflammatory markers with testosterone treatment.
• Health-related quality of life and functional performance measures were not preserved by testosterone therapy.

Conclusions:

• Adjunct testosterone therapy at 100 mg weekly did not improve cancer-related fatigue, inflammatory markers, quality of life, or functional measures in late-stage cancer patients.
• These findings do not support the use of testosterone for managing CRF or its associated symptoms in this patient population.
• Further research may be needed to explore other therapeutic targets for CRF.